Susanne Stowasser

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · New England Journal of Medicine · 2014 · 4.6K citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacotherapy +11

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine · 2019 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

Carlo Vancheri, Michael Kreuter, Luca Richeldi et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 297 citations

Medicine, Pharmacology, Pharmacotherapy +13